Third Rock’s faded Ember gets resuscitated in merger deal

Damian Garde Ember Therapeutics, a Third Rock Ventures-founded biotech startup that closed its doors late last year, is getting a second chance thanks to a small New York drug developer. FierceBiotech ...

Valeant closing in on $160-per-share Salix deal: Reuters

Carly Helfand There are reportedly at least three horses in the race to buy Salix Pharmaceuticals, but according to Reuters' sources, serial acquirer Valeant has the lead. FiercePharma ...

Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU

Eric Palmer Just days after Gilead COO John Milligan told investors to expect negotiations for its hep C franchise to unfold very quickly in Europe, Germany has said it has a deal to ...

India’s Cipla presses court to not honor Novartis Onbrez patent citing Lupin license deal

EJ Lane India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss ...

AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal

Carly Helfand AstraZeneca CEO Pascal Soriot has said he wants to dominate in the respiratory field. Actavis CEO Brent Saunders has no such ambitions. Now, the two have struck a deal. FiercePharma ...

Big shot investor plans £100M EU biotech fund, Genmab up on PhII data, J&J inks U.K. RA deal

Nick Paul Taylor In this week's EuroBiotech Report, after years of relying heavily on Neil Woodford's checkbook, early-stage British and European biotechs could soon have another ...

Astellas bets on Immunomic’s allergy vaccine in a $75M deal

Damian Garde Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan. FierceBiotech ...

GlaxoSmithKline CEO: Chin up, investors. Dividend’s safe, and Novartis deal awaits

Carly Helfand GlaxoSmithKline's shareholders may be expecting less-than-stellar sales next year as generics take their toll on respiratory behemoth Advair. But they still have plenty ...

Abbott, unfazed by political tensions, closes deal for Russia’s Veropharm

Carly Helfand Mounting political tensions between Russia and the West may have recently scared Germany's Fresenius out of a partnership in the country. But they won't spook ...

UPDATED: Perrigo snaps up OTC specialist Omega in deal worth $4.5B

Emily Wasserman Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market. ...

Almirall sends 719 employees to AstraZeneca as part of respiratory deal

Emily Wasserman AstraZeneca signed on the dotted line for Almirall, gaining access to the company's promising respiratory drug portfolio and products currently under development. ...

AstraZeneca builds cancer R&D dream house with $150M Definiens buyout, J&J deal

John Carroll FierceBiotech News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS